SCNI
Price
$1.61
Change
+$0.07 (+4.55%)
Updated
Sep 3 closing price
Capitalization
1.63M
ZLDAF
Price
$0.23
Change
-$0.06 (-20.69%)
Updated
Sep 2 closing price
Capitalization
3.2M
Interact to see
Advertisement

SCNI vs ZLDAF

Header iconSCNI vs ZLDAF Comparison
Open Charts SCNI vs ZLDAFBanner chart's image
Scinai Immunotherapeutics
Price$1.61
Change+$0.07 (+4.55%)
Volume$145.4K
Capitalization1.63M
Zelira Therapeutics
Price$0.23
Change-$0.06 (-20.69%)
Volume$100
Capitalization3.2M
SCNI vs ZLDAF Comparison Chart in %
Loading...
SCNI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCNI vs. ZLDAF commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCNI is a Buy and ZLDAF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (SCNI: $1.61 vs. ZLDAF: $0.23)
Brand notoriety: SCNI and ZLDAF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCNI: 10% vs. ZLDAF: 14%
Market capitalization -- SCNI: $1.63M vs. ZLDAF: $3.2M
SCNI [@Biotechnology] is valued at $1.63M. ZLDAF’s [@Biotechnology] market capitalization is $3.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCNI’s FA Score shows that 2 FA rating(s) are green whileZLDAF’s FA Score has 0 green FA rating(s).

  • SCNI’s FA Score: 2 green, 3 red.
  • ZLDAF’s FA Score: 0 green, 5 red.
According to our system of comparison, SCNI is a better buy in the long-term than ZLDAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCNI’s TA Score shows that 6 TA indicator(s) are bullish while ZLDAF’s TA Score has 3 bullish TA indicator(s).

  • SCNI’s TA Score: 6 bullish, 1 bearish.
  • ZLDAF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, SCNI is a better buy in the short-term than ZLDAF.

Price Growth

SCNI (@Biotechnology) experienced а +8.78% price change this week, while ZLDAF (@Biotechnology) price change was -12.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLDAF($3.2M) has a higher market cap than SCNI($1.63M). ZLDAF YTD gains are higher at: -40.731 vs. SCNI (-53.961). SCNI has higher annual earnings (EBITDA): 7.8M vs. ZLDAF (-3.17M). SCNI has higher revenues than ZLDAF: SCNI (452K) vs ZLDAF (40.9K).
SCNIZLDAFSCNI / ZLDAF
Capitalization1.63M3.2M51%
EBITDA7.8M-3.17M-246%
Gain YTD-53.961-40.731132%
P/E Ratio0.41N/A-
Revenue452K40.9K1,105%
Total Cash1.03MN/A-
Total Debt1.23MN/A-
FUNDAMENTALS RATINGS
SCNI vs ZLDAF: Fundamental Ratings
SCNI
ZLDAF
OUTLOOK RATING
1..100
2893
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7100
PRICE GROWTH RATING
1..100
9351
P/E GROWTH RATING
1..100
74100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCNI's Valuation (13) in the Pharmaceuticals Major industry is significantly better than the same rating for ZLDAF (94) in the null industry. This means that SCNI’s stock grew significantly faster than ZLDAF’s over the last 12 months.

SCNI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ZLDAF (100) in the null industry. This means that SCNI’s stock grew similarly to ZLDAF’s over the last 12 months.

SCNI's SMR Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for ZLDAF (100) in the null industry. This means that SCNI’s stock grew significantly faster than ZLDAF’s over the last 12 months.

ZLDAF's Price Growth Rating (51) in the null industry is somewhat better than the same rating for SCNI (93) in the Pharmaceuticals Major industry. This means that ZLDAF’s stock grew somewhat faster than SCNI’s over the last 12 months.

SCNI's P/E Growth Rating (74) in the Pharmaceuticals Major industry is in the same range as ZLDAF (100) in the null industry. This means that SCNI’s stock grew similarly to ZLDAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCNIZLDAF
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
N/A
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
87%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
SCNI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLDAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AU58.141.48
+2.61%
AngloGold Ashanti plc
ATHA0.39N/A
-0.41%
Athira Pharma
FDUS21.42-0.11
-0.51%
Fidus Investment Corp
FLD3.49-0.09
-2.51%
Fold Holdings Inc.
AKRO45.44-1.29
-2.76%
Akero Therapeutics

SCNI and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCNI has been closely correlated with NBY. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if SCNI jumps, then NBY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCNI
1D Price
Change %
SCNI100%
+0.65%
NBY - SCNI
88%
Closely correlated
+28.09%
NCNA - SCNI
88%
Closely correlated
-6.58%
TAOX - SCNI
88%
Closely correlated
+6.70%
RNAC - SCNI
86%
Closely correlated
-2.09%
AGEN - SCNI
86%
Closely correlated
-0.48%
More

ZLDAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLDAF has been loosely correlated with BMEA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLDAF jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLDAF
1D Price
Change %
ZLDAF100%
-20.57%
BMEA - ZLDAF
37%
Loosely correlated
+4.10%
QLGN - ZLDAF
33%
Loosely correlated
N/A
SCNI - ZLDAF
32%
Poorly correlated
+0.65%
LYEL - ZLDAF
27%
Poorly correlated
+2.98%
YECO - ZLDAF
26%
Poorly correlated
N/A
More